Aligos Therapeutics Inc. (NASDAQ:ALGS) finished Friday with a subtraction of -$0.05 to close at $0.95, a downside of -4.36 percent. An average of 535,920 shares of common stock have been traded in the last five days. There was a gain of $0.0030 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 243,390 shares traded, while the 50-day average volume stands at 137,358.
ALGS stock has decreased by -4.71% in the last month. The company shares reached their 1-month lowest point of $0.8401 on 12/29/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.84 and a high of $12.59 in 52 weeks. It has reached a new high 1 time so far this year and lost -91.97% or -$10.9171 in price. In spite of this, the price is down -92.43% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Aligos Therapeutics Inc. (ALGS) has a trailing price-to-sales (P/S) ratio at 3.98, the price-to-book (PB) ratio at 0.33.
The quick ratio of Aligos Therapeutics Inc. for the three months ended September 29 was 4.90, and the current ratio was 4.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $132.68 million compared to revenue of $4.36 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Aligos Therapeutics Inc.’s return on assets was -56.50%.
For the three-month period that ended September 29, Aligos Therapeutics Inc. had $55.86 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$18.62 million in the quarter, while revenues of -$19.92 million were shrunk -77.87%. The analyst consensus anticipated Aligos Therapeutics Inc.’s latest quarter earnings to come in at -$0.58 per share, but it turned out to be -$0.44, a 24.10% surprise. For the quarter, EBITDA amounted to -$18.11 million. Shareholders own equity worth $42.82 million.
From a technical analysis perspective, let’s take a brief look at Aligos Therapeutics Inc. (ALGS) price momentum. RSI 9-day as of the close on 30 December was 49.54%, suggesting the stock is Neutral, with historical volatility in this time frame at 107.31%.
As of today, ALGS’s price is $0.9437 +0.32% or $0.0030 from its 5-day moving average. ALGS is currently trading -1.26% lower than its 20-day SMA and -28.35% lower than its 100-day SMA. However, the stock’s current price level is -10.94% below the SMA50 and -63.07% below the SMA200.
The stochastic %K and %D were 43.42% and 37.17%, respectively, and the average true range (ATR) was 0.1155. With the 14-day stochastic at 47.02% and the average true range at 0.1088, the RSI (14) stands at 48.97%. The stock has reached -0.0090 on the 9-day MACD Oscillator while the 14-day reading was at -0.0114.
Piper Sandler downgraded Aligos Therapeutics Inc. (NASDAQ: ALGS) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for Aligos Therapeutics Inc. (ALGS) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ALGS, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is ALGS’s price target for the next 12 months?
Analysts predict a range of price targets between $1.20 and $5.00, with a median target of $2.00. Taking a look at these predictions, the average price target given by analysts for Aligos Therapeutics Inc. (ALGS) stock is $2.55.